PubMed Health⌕ Search

Biomedical subjects

D Nori

Publications and source records attributed to D Nori.

At least 19 recordsLinked to original sources

The effect of ionizing radiation on intraocular lenses.

BACKGROUND: The native crystalline lens is the principal shield against ultraviolet radiation (UV), damage to the human retina. Every year in the United States, more than one million patients undergo removal of the natural lens in the course of cataract surgery (phakectomy), at which time an intraocular lens (IOL) is placed in the lens capsule. The IOL thenceforth serves as the principal barrier to ultraviolet radiation over the life of the implant, potentially for decades. The synthetic organic molecules of which IOLs are composed offer little UV protection unless ultraviolet-absorbing chromophores are incorporated into the lens material during manufacture. However, chromophores are alkenes potentially subject to radiolytic degradation. It is unknown whether ionizing radiation at clinical doses (e.g., to the brain or in the head-and-neck region) affects the UV-absorbing capacity of chromophore-bearing IOLs and consequently exposes the retina to potentially chronic UV damage. In addition, the polymers of which IOLs are composed are themselves subject to radiation damage, which theoretically might result in optical distortion in the visible light range. OBJECTIVE: To determine whether megavoltage photon ionizing radiation alters the absorption spectra of ultraviolet-shielding polymethylmethacrylate (PMMA) and organopolysiloxane (silicone) intraocular lenses (IOLs) in the UV (280 nm < or = lambda < 400 nm), visible (400 nm < or = lambda < or = 700 nm), and low-end near-infrared (700 nm < lambda < or = 830 nm) ranges. DESIGN: Prospective, nonrandomized trial of dose-paired IOL cohorts. METHODS: Fourteen IOLs, seven of PMMA (Chiron 6842B) and seven of silicone (IOLAB L141U), were paired and examined for absorption spectra in 1-nm intervals over the range lambda = 280-830 nm on a Cary 400 deuterium and quartz halogen source-lamp UV/visible spectrophotometer before and after undergoing megavoltage ionizing irradiation to doses of 2, 5, 10, 20, 40, 60, and 100 Gray, respectively. Because of artifactual aberrations inherent in analyzing convex lenses on a conventional flat-plate spectrophotometer, post-irradiation absorption spectra were subsequently reanalyzed on a Cary 300 spectrophotometer outfitted with a Labsphere Diffused Reflectance Accessory (DRA-CA-30-I) incorporating a Spectralon-coated integrating sphere. MAIN OUTCOME MEASURES: Primary: Changes in UV absorbance after irradiation. Secondary: Changes in visible and low-end near-infrared absorbance after irradiation. RESULTS: Photon ionizing radiation in the 2-Gy to 100-Gy range produced no detectable alterations in the UV (280 nm < or = lambda < 400 nm), visible (400 nm < or = lambda < or = 700 nm), or low-end near-infrared (700 nm < lambda < or = 830 nm) absorption spectra of any of the lenses irradiated. However, silicone IOLs as a group revealed peak post-irradiation UV absorption at a shorter wavelength than did PMMA IOLs, with marginally greater UV transmission at the uppermost extreme of the UV spectrum (lambda = 384.5-400 nm). CONCLUSIONS: At clinically relevant doses used in radiation therapy, megavoltage photon ionizing radiation produces no significant alterations in the absorption spectra of PMMA and silicone IOLs over the range lambda = 280- 830 nm. These findings indicate that, even at supraclinical doses, the UV-absorbing capacity of chromophore-bearing PMMA and silicone IOLs remains unimpaired. It is not clear whether the lower UV peak of silicone lenses represents a radiation effect or a peculiarity of the chromophore used in the lenses tested.

Humans↗

Bullous pemphigoid masquerading as acute radiation dermatitis: case report.

We report the first case of bullous pemphigoid complicating radiation therapy for vulvar cancer. Shortly after completion of postoperative radiation therapy for a TIN1 vulvar carcinoma, the patient presented with a rash that started within, but continued to extend, well beyond the radiation field. A biopsy of the lesions confirmed the diagnosis of bullous pemphigoid, and she had prompt clinical resolution with systemic tetracycline and steroids.

Acute Disease↗

Practical considerations in setting up an intracoronary brachytherapy program: results of a multicenter survey.

PURPOSE: To identify logistic issues faced by radiation oncologists in initiating intracoronary radiation therapy (RT) and to delineate their role in these procedures. MATERIALS AND METHODS: Radiation oncologists from 12 sites (with combined experience of >500 cases) that participated in a randomized, double-blinded study of intracoronary RT completed a questionnaire that included demographics and experience, regulatory issues, scheduling and interaction with patients, time commitment, involvement of the radiation oncologist, and ideas for overcoming hurdles. RESULTS: Licensing was perceived as a substantial hurdle; Nuclear Regulatory Commission approval took more than 5 months at five of 12 sites. At two higher-volume sites, 10-20 procedures were performed per week; 75% of these radiation oncologists did not see the patient prior to the procedure and were not involved in obtaining informed consent. The mean time spent per case was 30-90 minutes; however, there were major concerns about case scheduling (<50% had any input in case scheduling) and after-hours coverage. Radiation oncologists performed fluoroscopy and cineangiography at most centers (92% and 83%); they also performed intracoronary contrast material injections (67%), interpreted intravascular ultrasonographic images (42%), and repositioned the intracoronary RT catheter (33%). CONCLUSION: The authors identify several issues that need to be addressed before intracoronary RT becomes a part of widespread clinical practice. Close collaboration between cardiologists and radiation oncologists at various levels is required to ensure that patients derive maximal benefit from this new technology.

Angioplasty, Balloon, Coronary↗

Radiation therapy to prevent stenosis of peripheral vascular accesses.

Postangioplasty vascular restenosis is a major clinical problem. There has been an upsurge in interest in the use of postangioplasty endovascular brachytherapy in preventing vascular restenosis. Much of the work in this field is being driven by the interventional cardiology community, and there has been a tendency to use a one-size-fits-all approach. This article reviews the application of vascular radiation therapy to prevent postangioplasty dialysis access restenosis. We identify the key features of dialysis accesses that distinguish them from other clinical situations of postangioplasty restenosis. The implications for interventional radiation therapy in this setting are discussed at length, including the need for a centering device, the issues involved in isotope selection, and the advantages offered by external-beam radiation therapy.

Angioplasty, Balloon↗

Nutrient dilution before and after X irradiation increases the radioresistance of log- and plateau-phase Chinese hamster V79 cells.

Previous observations have shown that cells cultured in standard growth medium (100%) demonstrated similarly enhanced survival when incubated postirradiation either in non-growth-promoting conditioned medium or in growth-promoting 40% growth medium (Reddy and Lange, Radiat, Res. 119, 338-347, 1989). From these results, it was suggested that nutrient dilution altered radiosensitivity by a mechanism independent of progression of cells through the cell cycle. In this study, we have examined the effects on radiosensitivity of incubation in 40% growth medium prior to irradiation on both log- and plateau-phase Chinese hamster V79 cells and the effects on the distribution of cells in the cell cycle of incubation in 40% or 100% growth medium before and after irradiation. Radioresistance increased by a factor of 1.5-1.6 compared to 100% growth medium for both log-phase and plateau-phase cells cultured in 40% growth medium prior to X irradiation and incubated in either 40% growth medium or conditioned medium after X irradiation. The cell cycle distributions of log-phase cells in 100% and 40% growth medium before irradiation were identical. The change in cell cycle distribution induced by 10 Gy did not differ among log-phase cells incubated for 3 h postirradiation in 100% growth medium, 40% growth medium or conditioned medium. These results, in addition to supporting our previous conclusions, demonstrate that culturing prior to irradiation in 40% growth medium alone increases cell survival and that incubation in 40% growth medium before and after irradiation maximizes the survival of V79 cells.

Animals↗

The pitfalls and complications of radiation therapy for esophageal carcinoma.

Radiation therapy is an important part of the management of esophageal cancer. Effective radiation therapy, however, requires careful evaluation of the tumor and the patient, cognizance of the tolerance of normal tissues in the area to the type of chemotherapy or surgical procedure employed, detailed planning, and streamlined delivery. When combining radiation therapy with other modalities of cancer treatment, physicians of both disciplines must be aware of the ability of one modality to potentiate the toxicity of the other. Therapy prescribed with the intention to cure and achieve long-term survival must be planned with consideration for the quality of life of the patient.

Brachytherapy↗

Management of peripheral vascular disease: innovative approaches using radiation therapy.

Despite the early successes at vascular recanalization with percutaneous transluminal angioplasty, vascular restenosis has emerged as a clinical problem of near epidemic proportions. Numerous pharmacologic and mechanical adjuncts have been tried with little success. Over the last few years, there have major advances in our understanding of the biology of the restenotic process. The process is now recognized as a proliferation disorder, and therapies akin to those used in the treatment of malignant diseases are being explored. Endovascular brachytherapy has shown strong potential in controlling this pathologic proliferative process in the laboratory and in early clinical studies. In this review we discuss some of the basic issues involved in vascular restenosis and the current status of endovascular brachytherapy.

Arteriosclerosis↗